Drug resistance-related microRNAs in esophageal cancer

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1487-1494

  Hong, Liu ^a   Han, Yu ^a   Lu, Qun ^b   Zhang, Hongwei ^a   Zhao, Qingchuan ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Esophageal cancer; microRNA; miR 141; miR 148a; miR 200c; miR 214; miR 27a; miR 296; miR 483

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DOXORUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; LET 7 PROTEIN; MICRORNA; MICRORNA 141; MICRORNA 148A; MICRORNA 16; MICRORNA 200C; MICRORNA 21; MICRORNA 214; MICRORNA 27A; MICRORNA 296; MICRORNA 451; MICRORNA 483; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

3' UNTRANSLATED REGION; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 12; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; OVERALL SURVIVAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS;

EID: 84867313655     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.711309     Document Type: Review

References (51)

1. Hong L, Li S, Han Y, et al. Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 2011;20(5):637-44
2. Hong L, Han Y, Li S, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10(12):1693-701
3. Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr 2011;15(3):141-51
4. David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol 2011;11(6):612-16
5. Millan MJ. MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues. Curr Opin Pharmacol 2011;11(1):11-22
6. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110(3):483-95
7. Imanaka Y, Tsuchiya S, Sato F, et al. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011; 56(4):270-6
8. Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011;17(9):3029-38
9. Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63
10. Hummel R, Watson DI, Smith C, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011;15(3):429-38
11. Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010;55(9):2545-51
12. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010;17(8):523-31
13. Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr 2011;15(3):141-51
14. Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007;26(5):311-20
15. Matsushima K, Isomoto H, Kohno S, et al. MicroRNAs and esophageal squamous cell carcinoma. Digestion 2010;82(3):138-44
16. Senanayake U, Das S, Vesely P, et al. MiR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012;33(5):1014-21
17. Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 2011;17(12):1627-35
18. Smith CM, Watson DI, Leong MP, et al. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011;17(8):1036-44
19. Gonzales JC, Fink LM, Goodman OB Jr, et al. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9(1):39-45
20. Hu M, Xia M, Chen X, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010;55(8):2365-72
21. Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 2011;32(3):583-8
22. Xu Y, Brenn T, Brown ER, et al. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act Abstract: tumour suppressors. Br J Cancer 2012;106(3):553-61
23. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12(3):273-85
24. Chen ML, Liang LS, Wang XK. MiR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1. Clin Exp Metastasis 2012;29(5):457-69
25. Rokavec M, Wu W, Luo JL. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell 2012;45(6):777-89
26. Wu Y, Xiao Y, Ding X, et al. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011;6(12):e29043
27. Zheng B, Liang L, Wang C, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res 2011;17(24):7574-83
28. Liffers ST, Munding JB, Vogt M, et al. MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest 2011;91(10):1472-9
29. Hummel R, Hussey DJ, Michael MZ, et al. MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol 2011;18(1):253-60
30. Zhou X, Zhao F, Wang ZN, et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 2012;27(2):447-54
31. Zhang H, Li Y, Huang Q, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ 2011;18(11):1702-10
32. Robson JE, Eaton SA, Underhill P, et al. MicroRNAs 296 and 298 are imprinted and part of the GNAS/Gnas cluster and miR-296 targets IKBKE and Tmed9. RNA 2012;18(1):135-44
33. Langenkamp E, Zwiers PJ, Moorlag HE, et al. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anticancer Drugs 2012;23(2):161-72
34. Yoon AR, Gao R, Kaul Z, et al. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region. Nucleic Acids Res 2011;39(18):8078-91
35. Vaira V, Faversani A, Dohi T, et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012;31(1):27-38
36. Cazanave SC, Mott JL, Elmi NA, et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res 2011;52(8):1517-25
37. Urbich C, Kaluza D, Fromel T, et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood 2012;119(6):1607-16
38. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011;30:55
39. Feng DD, Zhang H, Zhang P, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011;15(10):2164-75
40. Spruck C MiR-27a regulation of SCF (Fbw7) in cell division control and cancer. Cell Cycle 2011;10(19):3232-3
41. Ma N, Li F, Li D, et al. Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem 2012;361(1-2):337-43
42. Patterson EE, Holloway AK, Weng J, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011;117(8):1630-9
43. Veronese A, Lupini L, Consiglio J, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010;70(8):3140-9
44. Bar-Eli M Searching for the 'melanomiRs': miR-214 drives melanoma metastasis. EMBO J 2011;30(10):1880-1
45. Hong L, Han Y, Li S, et al. Role of ZNRD1 (zinc ribbon domain-containing 1) in angiogenesis of leukaemia cells. Cell Biol Int 2011;35(4):321-4
46. Feng Y, Cao JH, Li XY, et al. Inhibition of miR-214 expression represses proliferation and differentiation of C2C12 myoblasts. Cell Biochem Funct 2011;29(5):378-83
47. Derfoul A, Juan AH, Difilippantonio MJ, et al. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011;32(11):1607-14
48. van Mil A, Grundmann S, Goumans MJ, et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res 2012;93(4):655-65
49. Wang YS, Wang YH, Xia HP, et al. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev 2012; 13(1):255-60
50. Bader AG, Brown D, Stoudemire J, et al. Developing therapeutic microRNAs for cancer. Gene Ther 2011;18(12):1121-6
51. Gandellini P, Profumo V, Folini M, et al. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011;15(3):265-79